AMPH was too aggressive with price cutting. Would have made more sense to keep price similar to other generics and slowly take the market. When you have only one other generic and an authorized generic on the market play smart and you still make a lot of money having 25% of the 4B market. Cannot understand why they didn't study game theory and slaughtered the golden goose.
Market Data 
Markets 
AI
